Devyser appoints Carnegie Investment Bank AB as liquidity provider

Report this content

Devyser Diagnostics AB (publ) (“Devyser”) has appointed Carnegie Investment Bank AB (publ) (”Carnegie”) as liquidity provider for the company’s shares listed on Nasdaq First North Growth Market. The arrangement is in accordance with the framework of Nasdaq Stockholm’s rules on liquidity providers.


In the role of liquidity provider Carnegie undertakes to continuously quote prices for the Devyser share in accordance with the from time-to-time applicable minimum requirements for liquidity providers set out by Nasdaq Stockholm. The purpose is to improve the liquidity of the share and reduce the spread between the buying and selling price. Carnegie’s assignment commences on November 1, 2022.


The information was submitted for publication by the contact persons below on October 31, 2022 at 11:00 CET.


For more information, please contact: 

Fredrik Alpsten, CEO  

Telephone: +46 706 673 106 


Sabina Berlin, CFO 
Telephone: +46 739 519 502 


About Devyser Diagnostics AB (publ) 


Devyser develops, produces, and sells genetic testing kits to laboratories in more than 45 countries. The products are used for advanced DNA testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient monitoring. Devyser’s products simplify complex genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. The company was founded in 2004 and is based in Stockholm, Sweden.

Devyser’s shares are listed on the Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB. For more information, visit